Recent Company News

• 05:31 PM ET Oct 19, 2025
  

  Immutep presents two poster presentations focusing on changing treatment paradigm in first line non-small cell lung cancer at ESMO (A$0.31, 0.00)

• 05:24 PM ET Oct 19, 2025
  

  Immutep presents positive data from EFTISARC-NEO Phase II trial at ESMO (A$0.31, 0.00)

• 11:02 AM ET Oct 16, 2025
  

  StreetAccount Summary - US unusual volume traders

• 09:35 PM ET Aug 04, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 05:30 PM ET Oct 12, 2025
  

  Immutep receives positive FDA feedback regarding successful completion of Project Optimus requirements and agreement on 30 mg as optimal biological dose for efti (A$0.31, 0.00)

• 05:41 PM ET Oct 08, 2025
  

  Immutep reports TACTI-004 Phase III trial has now enrolled and randomised over 170 patients (A$0.29, 0.00)

• 07:11 PM ET Sep 07, 2025
  

  Immutep notes abstract for EFTISARC-NEO Phase II investigator initiated trial has been accepted for oral presentation at CTOS (A$0.24, 0.00)

• 07:33 PM ET Aug 28, 2025
  

  Immutep reports FY NPAT (A$61.4M) vs FactSet (A$59.6M) [2 est, (A$61)-(58.2M)] (A$0.25, 0.00)